Amarin recently gained approval from the Food and Drug Administration for its hypertriglyceridemia therapeutic Vascepa. Its chief rival, Lovaza, which is produced by GlaxoSmithKline, brought in more than $900 million in sales in fiscal 2011, and analysts project that Vascepa can capture a significant portion of this market.
Given Vascepa's market potential, speculation in the blogosphere is rising that Amarin could be an attractive acquisition target. In this video, health care bureau chief Brenton Flynn talks with analyst Max Macaluso about the feasibility of an Amarin buyout.
Amarin shareholders enjoyed massive returns this summer in the run-up to Vascepa's approval, but the biotech space is rife with binary events. It's essential to balance the speculative stocks in your portfolio with dependable blue-chip companies that you can rely on. The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called "Secure Your Future With 9 Rock-Solid Dividend Stocks," and you can access your free copy today. Just click here to discover the winners we've picked.
Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.